Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We explore how the brain processes emotional information and how this is influenced by brain chemicals and medicines. This helps us to understand disorders such as depression and anxiety and to understand and contribute to the development of drug and psychological treatments.

The Psychopharmacology and Emotion Research Laboratory explores the ways in which the brain processes emotional information and how this is affected by neurotransmitters such as serotonin, noradrenaline and dopamine. As well as telling us about normal brain function, this may help us understand emotional disorders such as depression and anxiety and how these may be helped by drug treatments that affect neurotransmitter function. We attempt to understand how conventional treatments may work, how mechanisms underlying treatment efficacy interact with psychological treatments, and also whether we can predict new candidate treatments for depression and anxiety using these experimental medicine models.

 

The group comprises a multidisciplinary team of psychiatrists, psychologists, pharmacologists and neuroscientists and aims to explore these questions using human models of cognitive and emotional processing. Our methodologies include psychopharmacological challenges, neuropsychological testing, transcranial magnetic stimulation (TMS) and functional neuroimaging with fMRI, MEG and PET in healthy volunteers, patient and at-risk groups.

 

A major output of the group has been the development of a human model of antidepressant drug action (the Cognitive Neuropsychological Model; Harmer et al., 2009, British Journal of Psychiatry), based on the results of a series of studies which showed that antidepressant drugs bias emotional processing towards positive information much earlier than antidepressant effects on mood can be detected. Such changes are believed to contribute to the recovery from depression with the delay in antidepressants’ clinical efficacy arising from the need to translate the changes in emotional processing into subjective improvement in mood through interactions with the environment and the gradual relearning of non-depressive, emotional associations.

Selected publications

Online behavioural activation during the COVID-19 pandemic decreases depression and negative affective bias.

Journal article

Ruzickova T. et al, (2023), Psychol Med, 53, 795 - 804

A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings.

Journal article

Pulcu E. et al, (2022), Mol Psychiatry, 27, 81 - 87

Translating the promise of 5HT4 receptor agonists for the treatment of depression.

Journal article

Murphy SE. et al, (2021), Psychol Med, 51, 1111 - 1120

Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment.

Journal article

Godlewska BR. and Harmer CJ., (2021), Psychopharmacology (Berl), 238, 1265 - 1278

Lithium modulates striatal reward anticipation and prediction error coding in healthy volunteers.

Journal article

Volman I. et al, (2021), Neuropsychopharmacology, 46, 386 - 393

Related research themes